Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12
Jimenez-Guardeno, J. M.; Ortega-Prieto, A. M.; Menendez Moreno, B.; Maguire, T. J. A.; Diaz Hernandez, J. I.; Diez Perez, J.; Zuckerman, M.; Mercadal Playa, A.; Cordero Deline, C.; Malim, M. H.; Martinez-Nunez, R. T.
Show abstract
The COVID-19 pandemic has accelerated the need to identify new therapeutics at pace, including through drug repurposing. We employed a Quadratic Unbounded Binary Optimization (QUBO) model, to search for compounds similar to Remdesivir (RDV), the only antiviral against SARS-CoV-2 currently approved for human use, using a quantum-inspired device. We modelled RDV and compounds present in the DrugBank database as graphs, established the optimal parameters in our algorithm and resolved the Maximum Weighted Independent Set problem within the conflict graph generated. We also employed a traditional Tanimoto fingerprint model. The two methods yielded different lists of compounds, with some overlap. While GS-6620 was the top compound predicted by both models, the QUBO model predicted BMS-986094 as second best. The Tanimoto model predicted different forms of cobalamin, also known as vitamin B12. We then determined the half maximal inhibitory concentration (IC50) values in cell culture models of SARS-CoV-2 infection and assessed cytotoxicity. Lastly, we demonstrated efficacy against several variants including SARS-CoV-2 Strain England 2 (England 02/2020/407073), B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta). Our data reveal that BMS-986094 and different forms of vitamin B12 are effective at inhibiting replication of all these variants of SARS-CoV-2. While BMS-986094 can cause secondary effects in humans as established by phase II trials, these findings suggest that vitamin B12 deserves consideration as a SARS-CoV-2 antiviral, particularly given its extended use and lack of toxicity in humans, and its availability and affordability. Our screening method can be employed in future searches for novel pharmacologic inhibitors, thus providing an approach for accelerating drug deployment.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Deep Learning-based Ligand Design using Shared Latent Implicit Fingerprints from Collaborative Filtering 96%
- Retro Drug Design: From Target Properties to Molecular Structures 96%
- Streamlining Computational Fragment-Based Drug Discovery through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening 95%
Similar papers in this journal
- Discovery of Z1362873773: A Novel Fascin Inhibitor from a Large Chemical Library for Colorectal Cancer 96%
- Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning 95%
- HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2 95%
Similar papers in this journal
Similar papers in this journal
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 96%
- A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2 94%
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 94%
Similar papers in this journal
- Machine learning approaches identify chemical features for stage-specific antimalarial compounds 95%
- Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-based Classifiers 94%
- Support Vector Machine based prediction models for drug repurposing and designing novel drugs for colorectal cancer 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.